Progress in treatment of follicular lymphoma / 白血病·淋巴瘤

Follicular lymphoma (FL) is a kind of indolent non-Hodgkin lymphoma (iNHL), which origins from follicle germinal center. Multiple researches reported the latest development about treatment of FL in the 58th American Society of Hematology (ASH) Annual Meeting. The outcomes of clinical trials in which GAl01 combined with chemotherapy and bendamustine in combination with 90Y-ibritumomab tiuxetan for the advanced stage FL were exciting. Relapsed/refractory FL patients who receive tandem autologous followed by nonmyeloablative allogeneic transplantation could acquire preferable remissions. With the emerging of novel drugs including inhibitor of bcl-2 or PI3K and antibody drug conjugate, more and more improvements of efficacy and remission were made in the treatment of relapsed/refractory FL therapy and remission.

Treatment progress of diffuse large B cell lymphoma: reports from the 56th American Society of Hematology annual meeting / 白血病·淋巴瘤

Diffuse large B cell lymphoma (DLBCL) is one of the most common non-Hodgkin lymphoma (NHL).Since the appearance of rituximab,the most common first-line therapy is rituximab in combination with chemotherapy.About 70 percent of patients could achieve complete remission (CR) and be cured finally.But one third of patients could not reach CR after frontline treatment or relapse early,especially the elder patients or high risk ones.In the 56th American Society of Hematology (ASH) annual meeting,a plenty of treatments focusing on these patients brought encouraging results,which makes it possible to further improve the CR rate.The progresses in relapse/refractory,high risk and special site DLBCL will be summarized in this paper based on the reports in the 56th ASH annual meeting.

Treatment progress of follicular lymphoma: reports from the 56th American Society of Hematology annual meeting / 白血病·淋巴瘤

Follicular lymphoma (FL) is a kind of indolent Non-Hodgkin lymphoma (NHL),which stems from follicle germinal center.A lot of research reported the latest development about treatment of FL in the 56th American Society of Hematology (ASH) annual meeting.Effect of radiotherapy for patients at low stage was determined,while the outcomes of clinical trials in which monoclonal antibody (GA101) in combination with chemotherapy for the advanced stage FL were exciting.In rituximab era,relapsed/refractory FL patients who receive stem cell transplantation could acquire preferable remissions.Several novel drugs (inhibitor of BTK or PI3K) for relapsed/refractory FL played a role of guidepost with the progression of corresponding trials.